Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease.

Sebastian CremerLisa PilgramAlexander BerkowitschMelanie StecherSiegbert RiegMariana ShumliakivskaDenisa BojkovaJulian Uwe Gabriel WagnerGalip Servet AslanChristoph D Spinner Guillermo LuxánFrank HansesSebastian DolffChristiane PiepelClemens RuppertAndreas GuentherMaria Madeleine RüthrichJörg Janne VehreschildKai WilleMartina HaselbergerHanno HeuzerothArne HansenThomas EschenhagenJindrich CinatlSandra CiesekStefanie DimmelerStefan BorgmannAndreas Zeihernull null

Published in: PloS one (2021)

These data suggest a beneficial effect of ARBs on disease severity in patients with cardiovascular comorbidities and COVID-19, which is linked to dampened systemic inflammatory activity.

Keyphrases

angiotensin ii
coronavirus disease
angiotensin converting enzyme
sars cov
vascular smooth muscle cells
oxidative stress
electronic health record
big data
cardiovascular disease
risk factors
weight gain
binding protein
data analysis
deep learning
weight loss